Assembly Biosciences Inc Total Liabilities
Assembly Biosciences Inc total liabilities. Based on the latest financial reports, Assembly Biosciences Inc (ASMB) has total liabilities worth $25.18 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Assembly Biosciences Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Assembly Biosciences Inc (2008–2025)
Total liabilities of Assembly Biosciences Inc from 2008 to 2025. This chart illustrates how Assembly Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Assembly Biosciences Inc to see how much of total assets are deployed in long-term investments.
Assembly Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Assembly Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Voneseals Technology (Shanghai) Inc. A
SHE:301161
|
China | CN¥325.99 Million |
|
Regal Partners Global Investments Limited
AU:RG1
|
Australia | AU$121.10 Million |
|
Kura Sushi USA Inc
NASDAQ:KRUS
|
USA | $240.73 Million |
|
Genesco Inc
NYSE:GCO
|
USA | $831.59 Million |
|
Jiangsu Hengshang Energy Conservation Technology Co. Ltd. A
SHG:603137
|
China | CN¥1.74 Billion |
|
Shanghai Hollywave Electronic System Co. Ltd. A
SHG:688682
|
China | CN¥228.04 Million |
|
Wolfspeed, Inc.
NASDAQ:WOLF
|
USA | $7.63 Billion |
|
Lendingtree Inc
NASDAQ:TREE
|
USA | $590.86 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Assembly Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Assembly Biosciences Inc.
Liquidity & Leverage Metrics
Assembly Biosciences Inc Total Liabilities Ratios Explained
Assembly Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Assembly Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Assembly Biosciences Inc (2008–2025)
The table below shows the annual total liabilities of Assembly Biosciences Inc from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $50.84 Million | -40.75% |
| 2024-12-31 | $85.81 Million | -10.36% |
| 2023-12-31 | $95.73 Million | +400.40% |
| 2022-12-31 | $19.13 Million | -13.56% |
| 2021-12-31 | $22.13 Million | -48.14% |
| 2020-12-31 | $42.68 Million | -42.85% |
| 2019-12-31 | $74.67 Million | +30.10% |
| 2018-12-31 | $57.39 Million | +2.15% |
| 2017-12-31 | $56.18 Million | +208.01% |
| 2016-12-31 | $18.24 Million | +21.58% |
| 2015-12-31 | $15.00 Million | +18.56% |
| 2014-12-31 | $12.65 Million | +379.67% |
| 2013-12-31 | $2.64 Million | -3.91% |
| 2012-12-31 | $2.75 Million | +9.25% |
| 2011-12-31 | $2.51 Million | -15.96% |
| 2010-12-31 | $2.99 Million | -77.90% |
| 2009-12-31 | $13.53 Million | +31.00% |
| 2008-12-31 | $10.33 Million | -- |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase … Read more